DuPont de Nemours, Inc.: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Jul 31, 2020 and accepted by EDGAR at Jul 31, 2020, 10:36 ET.
Management's discussion and analysis
As filed, 72,331 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Effective August 31, 2017, pursuant to the merger of equals transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "Merger"). Prior to the Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the Merger Agreement. Historical Dow was determined to be the accounting acquirer in the Merger.
DowDuPont completed a series of internal reorganizations and realignment steps in order to separate into three, independent, publicly traded companies - one for each of its agriculture, materials science and specialty products businesses. DowDuPont formed two wholly owned subsidiaries: Dow Inc. ("Dow", formerly known as Dow Holdings Inc.), to serve as a holding company for its materials science business, and Corteva, Inc. ("Corteva"), to serve as a holding company for its agriculture business.
Effective as of 5:00 p.m. on April 1, 2019, DowDuPont completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock, par value $0.01 per share (the “Dow Common Stock”), to holders of the Company’s common stock, par value $0.01 per share (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”).
Effective as of 12:01 a.m. on June 1, 2019, DuPont de Nemours, Inc. (formerly known as DowDuPont Inc.), completed the separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock, par value $0.01 per share (the “Corteva Common Stock”), to holders of the Company’s common stock, par value $0.01 per share, as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “Distributions”).
Following the Corteva Distribution, the Company holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont" (the "Company"). Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD."
The results of operations of DuPont for the 2019 interim periods presented reflect the historical financial results of Dow and Corteva as discontinued operations, as applicable. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.
The statements of operations and pro forma statements of operations included in this report and as discussed below include costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with Financial Accounting Standards Codification 205, "Presentation of Financial Statements" ("ASC 205") and thus are reflected in the Company's results of continuing operations. A significant portion of these costs relate to Historical Dow and consist of leveraged services provided through service centers, as well as other corporate overhead costs related to information technology, finance, manufacturing, research & development, sales & marketing, supply chain, human resources, sourcing & logistics, legal and communications, public affairs & government affairs functions. These costs are no longer incurred by the Company following the Distributions.
On December 15, 2019, the Company entered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a tax-efficient Reverse Morris Trust transaction, (the "Intended N&B Transaction"). The transaction is expected to close in the first quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by DuPont of an opinion of tax counsel. The financial results of the N&B Business are included in continuing operations for the periods presented.
RECENT DEVELOPMENTS
COVID-19
The novel coronavirus (“COVID-19”) pandemic has resulted in significant economic disruption and continues to adversely impact the broader global economy, including certain of the Company’s customers and suppliers. Given the dynamic nature of this situation, the Company cannot reasonably estimate the impacts of COVID-19 on its financial condition, results of operations or cash flows into the foreseeable future. The ultimate extent of the effects of the COVID-19 pandemic on the Company is highly uncertain and will depend on future developments, and such effects could exist for an extended period of time even after the pandemic subsides.
During the second quarter of 2020, the Company benefited from COVID-19 related demand in certain markets, principally personal protection, health & wellness and electronics. Although management currently expects strong demand from certain markets to continue into the third quarter of 2020, the COVID-19 pandemic is expected to continue to adversely impact demand in automotive, aerospace, commercial construction, oil & gas, and select industrial end-markets. In response to this uncertainty, the Company has delayed certain capital investments in select sectors, and has idled production at several manufacturing sites, predominantly production plants in the Transportation & Industrial segment.
In addition, in response to COVID-19 related market disruption and uncertainties, the Company has proactively taken steps to enhance its liquidity position. In April 2020, the Company entered into a $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility") which replaced its $750 million 364-day revolving credit facility (the “Old 364-Day Revolving Credit Facility”), and completed a public underwritten offering of $2 billion of 2.169 percent fixed rate notes due May 1, 2023 (the “May Debt Offering”). Refer to Liquidity and Capital Resources for more information.
Transportation & Industrial Impairments
In the second quarter of 2020, continued near-term demand weakness in global automotive production resulting from the COVID-19 pandemic, along with revised views of recovery based on third party market information, served as a triggering event requiring the Company to perform an impairment analysis of the goodwill associated with its Transportation & Industrial reporting unit as of June 30, 2020. As a result of the analysis performed, the Company recorded pre-tax, non-cash impairment charges related to goodwill of $2,498 million. The charges were recognized in "Goodwill impairment charges" in the interim Consolidated Statements of Operations. Refer to Note 11 of the interim Consolidated Financial Statements. In connection with the Transportation & Industrial impairment analysis, the Company also recorded pre-tax, non-cash impairment charges of $21 million related to indefinite-lived intangible assets. The charges were recognized in “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations. Refer to Note 5 of the interim Consolidated Financial Statements.
Dividends
On April 29, 2020, the Company announced that its Board of Directors declared a second quarter dividend of $0.30 per share, paid on June 15, 2020, to shareholders of record on May 29, 2020.
On June 25, 2020, the Company announced that its Board of Directors declared a third quarter dividend of $0.30 per share payable on September 15, 2020, to shareholders of record on July 31, 2020.
SELECTED FINANCIAL DATA
In millions, except per share amounts
| Three Months Ended June 30, 2020 | 2019 | Six Months Ended June 30, 2020 | 2019 | |
|---|---|---|---|---|
| Net sales | $4,828 | $5,468 | $10,049 | $10,882 |
| Cost of sales | $3,291 | $3,496 | $6,609 | $7,117 |
| Percent of net sales | 68.2% | 63.9% | 65.8% | 65.4% |
| Research and development expenses | $209 | $232 | $445 | $499 |
| Percent of net sales | 4.3% | 4.2% | 4.4% | 4.6% |
| Selling, general and administrative expenses | $541 | $642 | $1,174 | $1,368 |
| Percent of net sales | 11.2% | 11.7% | 11.7% | 12.6% |
| Effective tax rate - continuing operations | 1.4% | (16.4)% | (0.3)% | (5.8)% |
| Net loss available for DuPont common stockholders | $(2,478) | $(571) | $(3,094) | $(50) |
| Loss per common share – basic | $(3.37) | $(0.76) | $(4.20) | $(0.07) |
| Loss per common share – diluted | $(3.37) | $(0.76) | $(4.20) | $(0.07) |
RESULTS OF OPERATIONS
In millions
| Summary of Sales Results | Three Months Ended June 30, 2020 | 2019 | Six Months Ended June 30, 2020 | 2019 |
|---|---|---|---|---|
| Net sales | $4,828 | $5,468 | $10,049 | $10,882 |
The following table summarizes sales variances by segment and geographic region from the prior year:
Sales Variances by Segment and Geographic Region
| Percentage change from prior year | Three Months Ended June 30, 2020 Local Price & Product Mix | Currency | Volume | Portfolio & Other | Total | Six Months Ended June 30, 2020 Local Price & Product Mix | Currency | Volume | Portfolio & Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Electronics & Imaging | —% | (1)% | 7% | (1)% | 5% | —% | (1)% | 7% | —% | 6% |
| Nutrition & Biosciences | — | (2) | 1 | — | (1) | 1 | (2) | 1 | — | — |
| Transportation & Industrial | (5) | (1) | (28) | — | (34) | (5) | (1) | (18) | — | (24) |
| Safety & Construction | 2 | (1) | (10) | 2 | (7) | 2 | (1) | (7) | 2 | (4) |
| Non-Core | 2 | (1) | (22) | (9) | (30) | 2 | (1) | (17) | (9) | (25) |
| Total | —% | (1)% | (10)% | (1)% | (12)% | —% | (1)% | (6)% | (1)% | (8)% |
| U.S. & Canada | (1)% | —% | (16)% | —% | (17)% | (1)% | —% | (9)% | —% | (10)% |
| EMEA 1 | — | (2) | (16) | — | (18) | — | (2) | (10) | (1) | (13) |
| Asia Pacific | — | (1) | 1 | (1) | (1) | (1) | (1) | 1 | — | (1) |
| Latin America | 3 | (5) | (21) | (2) | (25) | 3 | (4) | (12) | (2) | (15) |
| Total | —% | (1)% | (10)% | (1)% | (12)% | —% | (1)% | (6)% | (1)% | (8)% |
1. Europe, Middle East and Africa.
The Company reported net sales for the three months ended June 30, 2020 of $4.8 billion, down 12 percent from $5.5 billion for the three months ended June 30, 2019, due to a 10 percent decrease in volume, a 1 percent unfavorable currency impact and a 1 percent decline in portfolio actions. Local price and product mix remained flat. Volume declined across all geographic regions with the exception of Asia Pacific where it increased 1 percent. Volume declined across all segments with the exception of Electronics & Imaging (up 7 percent) and Nutrition & Biosciences (up 1 percent). The most notable volume decreases were in Transportation & Industrial (down 28 percent) and Non-Core (down 22 percent). Currency was down 1 percent compared with the same period last year, driven primarily by Latin American currencies (down 5 percent). Portfolio and other changes contributed 1 percent of the sales decrease which impacted Non-Core (down 9 percent). Local price was flat compared with the same period last year. Local price increased in Latin America (up 3 percent) and in Safety & Construction (up 2 percent) and Non-Core (up 2 percent).
Net sales for the six months ended June 30, 2020 were $10.0 billion, down 8 percent from $10.9 billion for the six months ended June 30, 2019, due to a 6 percent decrease in volume, a 1 percent unfavorable currency impact and a 1 percent decline in portfolio actions. Local price and product mix remained flat. Volume declined across all geographic regions with the exception of Asia Pacific where it increased 1 percent. Volume declined across all segments with the exception of Electronics & Imaging (up 7 percent) and Nutrition & Biosciences (up 1 percent). The most notable volume decreases were in Transportation & Industrial (down 18 percent) and Non-Core (down 17 percent). Currency was down 1 percent compared with the same period last year, driven primarily by Latin American currencies (down 4 percent) and EMEA currencies (down 2 percent). Portfolio and other changes contributed 1 percent of the sales decrease which impacted Non-Core (down 9 percent). Local price and product mix was flat compared with the same period last year. Local price increased in Latin America (up 3 percent) and in all segments except Transportation & Industrial (down 5 percent) and Electronics & Imaging (flat).
Cost of Sales
Cost of sales was $3.3 billion for the three months ended June 30, 2020, down from $3.5 billion for the three months ended June 30, 2019 primarily due to lower sales volume, cost synergies, and currency impacts offset by approximately $160 million of charges associated with temporarily idling several manufacturing plants to align supply with demand due to COVID-19, mainly in the Transportation & Industrial segment.
Cost of Sales as a percentage of net sales for the three months ended June 30, 2020 was 68 percent compared with 64 percent for the three months ended June 30, 2019, driven mainly by the charges associated with temporary idling several manufacturing plans referenced above.
For the six months ended June 30, 2020, cost of sales was $6.6 billion, down from $7.1 billion for the six months ended June 30, 2019. Cost of sales decreased for the six months ended June 30, 2020 primarily due to lower sales volume, cost synergies, currency impacts, and lower costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions, offset by approximately $160 million of charges associated with temporarily idling several manufacturing plants to align supply with demand due to COVID-19, mainly in the Transportation & Industrial segment.
Cost of sales as a percentage of net sales for the six months ended June 30, 2020 was 66 percent compared with 65 percent for the six months ended June 30, 2019.
Research and Development Expenses ("R&D")
R&D expenses totaled $209 million in the second quarter of 2020, down from $232 million in the second quarter of 2019. R&D as a percentage of net sales was 4 percent for the three months ended June 30, 2020 and 2019.
For the first six months of 2020, R&D expenses totaled $445 million, down from $499 million in the first six months of 2019. R&D as a percentage of net sales was 4 percent and 5 percent for the six months ended June 30, 2020 and 2019, respectively.
The decrease for the six months ended June 30, 2020 compared with the same period of the prior year was primarily due to the absence of R&D costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions.
Selling, General and Administrative Expenses ("SG&A")
SG&A expenses were $541 million in the second quarter of 2020, down from $642 million in the second quarter of 2019 primarily due to productivity actions and reduced spending. SG&A as a percentage of net sales was 11 percent and 12 percent for the three months ended June 30, 2020 and 2019, respectively.
For the first six months of 2020, SG&A expenses totaled $1,174 million, down from $1,368 million in the first six months of 2019. SG&A as a percentage of net sales was 12 percent and 13 percent for the six months ended June 30, 2020 and 2019, respectively.
The decrease as compared with the same period of the prior year was primarily due to productivity actions and the absence of SG&A costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the Distributions.
Amortization of Intangibles
Amortization of intangibles was $528 million in the second quarter of 2020, up from $252 million in the second quarter of 2019. In the first six months of 2020, amortization of intangibles was $1,061 million, up from $508 million in the same period last year. The increase was primarily due to the amortization of the Nutrition and Biosciences tradenames that were reclassified to definite-lived intangibles in the fourth quarter of 2019 in connection with the Intended N&B Transaction.
Restructuring and Asset Related Charges - Net
Restructuring and asset related charges - net were $19 million in the second quarter of 2020, down from $137 million in the second quarter of 2019. The activity in the second quarter of 2020 included a $21 million impairment charge related to indefinite-lived intangible assets in the Transportation & Industrial segment, a $15 million charge related to the 2020 Restructuring Program, a $16 million credit related to the 2019 Restructuring Program and a $1 million credit related to the DowDuPont Cost Synergy Program. The charges in the second quarter of 2019 included a $63 million impairment charge related to an equity method investment, a $53 million charge related to the 2019 Restructuring Program and a $21 million charge related to the DowDuPont Cost Synergy Program.
In the first six months of 2020, restructuring and asset related charges - net were $423 million, up from $208 million in the same period last year. The activity for the six months of 2020 included a $270 million impairment charge related to long-lived assets in the Non-Core segment, a $21 million impairment charge related to indefinite-lived intangible assets in the Transportation & Industrial segment, a $126 million charge related to the 2020 Restructuring Program, a $2 million charge related to the 2019 Restructuring Program and a $4 million charge related to the DowDuPont Cost Synergy Program. The charges in the same period of 2019 related to the equity method investment impairment charge and 2019 Restructuring Program, both described above, as well as a $92 million charge related to the Synergy Program.
See Note 5 to the interim Consolidated Financial Statements for additional information.
Goodwill Impairment Charges
Goodwill impairment charges were $2,498 million in the second quarter of 2020, up from $1,175 million in the second quarter of 2019. Goodwill impairment charges were $3,031 million in the six months ended June 30, 2020, up from $1,175 million in the same period last year. In the second quarter of 2020, the charges relate to the Transportation and Industrial segment. In the first six months of 2020, the charges relate to the Transportation & Industrial and Non-Core segments. Goodwill impairment charges in the second quarter of 2019 and for the first six months of 2019 relate to the Nutrition & Biosciences and Non-Core segments. See Note 11 to the interim Consolidated Financial Statements for additional information.
Integration and Separation Costs
Integration and separation costs, which primarily reflect costs related to the post-Merger integration, activities related to the Distributions, and, during 2020, the Intended N&B Transaction, were $145 million in the second quarter of 2020, down from $347 million in the second quarter of 2019. In the first six months of 2020, integration and separation costs were $342 million, down from $958 million in the same period last year. The decline was primarily related to the timing of the Distributions.
Equity in Earnings of Nonconsolidated Affiliates
The Company's share of the earnings of nonconsolidated affiliates was $103 million in the second quarter of 2020, up from $49 million in the second quarter of 2019. In the first six months of 2020, the Company's share of the earnings of nonconsolidated affiliates was $142 million, up from $89 million in the first six months of 2019. The increases are primarily due to higher HSC Group equity earnings, mainly driven by customer settlements in the second quarter of 2020.
Sundry Income (Expense) - Net
Sundry income (expense) - net includes a variety of income and expense items such as foreign currency exchange gains or losses, interest income, dividends from investments, gains and losses on sales of investments and assets, non-operating pension and other post employment benefit plan credits or costs, and certain litigation matters. Sundry income (expense) - net in the second quarter of 2020 was expense of $14 million compared with expense of $19 million in the second quarter of 2019. The second quarter of 2020 included foreign currency exchange losses of $23 million, partially offset by income related to non-operating pension and other post employment benefits credits of $8 million. The second quarter of 2019 included a $48 million charge reflecting a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement included in miscellaneous income and foreign currency exchange losses of $17 million, partially offset by income related to non-operating pension and other post employment benefit credits of $18 million, a gain on the sale of assets of $10 million and interest income of $9 million.
In the first six months of 2020, sundry income (expense) - net was income of $197 million compared with income of $65 million in the first six months of 2019. The first six months of 2020 included benefits related to the sale of the Compound Semiconductor Solutions business unit of $197 million, income related to non-operating pension and other post employment benefit credits of $19 million and miscellaneous income of $12 million, partially offset by foreign currency exchange losses of $31 million. The first six months of 2019 included a gain on sale of assets of $63 million, interest income of $49 million and income related to non-operating pension and other post employment benefit plans of $39 million, partially offset by foreign currency exchange losses of $78 million.
Interest Expense
Interest expense was $193 million in the second quarter of 2020, up from $165 million in the second quarter of 2019. The increase primarily relates to incremental financing costs associated with the May Debt Offering and financing costs associated with the Intended N&B transaction.
In the first six months of 2020, interest expense was $376 million, up from $316 million in the same period last year. The increase primarily relates to financing facilities that were drawn after March 31, 2019 for the Company to operate on a stand-alone basis and complete the capital structures of Corteva and Dow in advance of their respective separations, which include the Term Loan Facilities and the DuPont Commercial Paper Program, as well as the factors noted above.
(Benefit from) Provision for Income Taxes on Continuing Operations
The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attribute. The effective tax rate on continuing operations for the second quarter of 2020 was 1.4 percent, compared with an effective tax rate of (16.4) percent for the second quarter of 2019. For the first six months of 2020, the effective tax rate on continuing operations was (0.3) percent, compared with (5.8) percent for the first six months of 2019.
The effective tax rate for the second quarter of 2020 and for the first six months of 2020 was principally the result of a non-tax-deductible goodwill impairment charge impacting the Transportation and Industrial segment in the second quarter and a non-tax-deductible goodwill impairment charge impacting the Non-Core segment in the first quarter. The tax rate in the second quarter of 2019 and for the first six months of 2019 was principally the result of the non-tax-deductible goodwill impairment charges impacting the Nutrition & Biosciences and Non-Core segments. See Note 11 to the interim Consolidated Financial Statements for additional information on the goodwill impairment charges.
Income from Discontinued Operations, Net of Tax
In the second quarter of 2020 and for the first six months of 2020, the Company did not have income from discontinued operations. In the second quarter of 2019 and for the first six months of 2019, income from discontinued operation, net of tax was $566 million and $1,212 million, respectively. The decrease period over period is attributable to the timing of the Distributions. Refer to Note 3 to the interim Consolidated Financial Statements for additional information.
Net Income Attributable to Noncontrolling Interests
Net income attributable to noncontrolling interests was $7 million in the second quarter of 2020, down from $34 million in the second quarter of 2019. For the first six months of 2020, net income attributable to noncontrolling interests was $13 million, down from $85 million for the same period last year. The decreases are attributable to the timing of the Distributions.
SUPPLEMENTAL UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
The following supplemental unaudited pro forma financial information (the “unaudited pro forma financial statements”) is derived from DuPont’s Consolidated Financial Statements, adjusted to give effect to certain events directly attributable to the Distributions. In contemplation of the Distributions and to achieve the respective credit profiles of each of the current companies, in the fourth quarter of 2018, DowDuPont borrowed $12.7 billion under the 2018 Senior Notes and entered the Term Loan Facilities with an aggregate principal amount of $3.0 billion. Additionally, DuPont issued approximately $1.4 billion in commercial paper in May 2019 in anticipation of the Corteva Distribution (the “Funding CP Issuance” together with the 2018 Senior Notes and the Term Loan Facilities, the "Financings"). The unaudited pro forma financial statements for the six months ended June 30, 2019 were prepared in accordance with Article 11 of Regulation S-X. The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the Distributions and the Financings (collectively the "Transactions"), (2) factually supportable and (3) with respect to the statements of operations, expected to have a continuing impact on the results. The unaudited pro forma statements of operations for the six months ended June 30, 2019 give effect to the pro forma events as if they had been consummated on January 1, 2018. There were no pro forma adjustments for the three and six months ended June 30, 2020 and for the three months ended June 30, 2019.
Restructuring or integration activities or other costs following the Distributions that may be incurred to achieve cost or growth synergies of DuPont are not reflected. The unaudited pro forma income statement provides shareholders with summary financial information and historical data that is on a basis consistent with how DuPont reports current financial information.
The unaudited pro forma financial statements are presented for informational purposes only, and do not purport to represent what DuPont's results of operations or financial position would have been had the Transactions occurred on the dates indicated, nor do they purport to project the results of operations or financial position for any future period or as of any future date.
Unaudited Pro Forma Combined Statements of Operations
2019
In millions, except per share amounts
| Six Months Ended June 30, DuPont 1 | Pro Forma Adjustments2 | Pro Forma | |
|---|---|---|---|
| Net sales | $10,882 | $— | $10,882 |
| Cost of sales | 7,117 | 22 | 7,139 |
| Research and development expenses | 499 | — | 499 |
| Selling, general and administrative expenses | 1,368 | — | 1,368 |
| Amortization of intangibles | 508 | — | 508 |
| Restructuring and asset related charges - net | 208 | — | 208 |
| Goodwill impairment charges | 1,175 | — | 1,175 |
| Integration and separation costs | 958 | (173) | 785 |
| Equity in earnings of nonconsolidated affiliates | 89 | — | 89 |
| Sundry income (expense) - net | 65 | — | 65 |
| Interest expense | 316 | 29 | 345 |
| Loss from continuing operations before income taxes | (1,113) | 122 | (991) |
| Provision for income taxes on continuing operations | 64 | 30 | 94 |
| Loss from continuing operations, net of tax | (1,177) | 92 | (1,085) |
| Net income attributable to noncontrolling interests of continuing operations | 13 | — | 13 |
| Net loss from continuing operations attributable to DuPont | $(1,190) | $92 | $(1,098) |
| Per common share data: | |||
| Loss per common share from continuing operations - basic | $(1.59) | $(1.47) | |
| Loss per common share from continuing operations - diluted | $(1.59) | $(1.47) | |
| Weighted-average common shares outstanding - basic | 749.6 | 749.6 | |
| Weighted-average common shares outstanding - diluted | 749.6 | 749.6 |
1. See the historical U.S. GAAP Consolidated Statements of Operations.
2. Certain pro forma adjustments were made to illustrate the estimated effects of the Transactions, assuming that the Transactions had occurred on January 1, 2018. The adjustments include the impact to "Cost of sales" of different pricing than historical intercompany and intracompany practices related to various supply agreements entered into with the Dow Distribution, adjustments to "Integration and separation costs" to eliminate one-time transaction costs directly attributable to the Distributions, and adjustments to "Interest expense" to reflect the impact of the Financings.
SEGMENT RESULTS
In the first quarter of 2020, in preparation for the Intended N&B Transaction, DuPont changed its management and reporting structure to realign costs associated with its polysaccharides pre-commercial activities from the Non-Core segment to the N&B segment. The reporting changes have been retrospectively reflected in the following discussion of segment results for all periods presented. Refer to Note 21 to the interim Consolidated Financial Statements for additional information.
Prior to April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is pro forma Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assessed performance and allocates resources. The Company defines pro forma Operating EBITDA as pro forma earnings (i.e., pro forma “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post employment benefits (“OPEB”) / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted for significant items. Effective April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's CODM assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures can be found in Note 21 to the interim Consolidated Financial Statements. Prior year data has been updated to conform with the current year presentation.
Pro forma adjustments used in the calculation of pro forma Operating EBITDA were determined in accordance with Article 11 of Regulation S-X and were derived from DuPont's historical Consolidated Financial Statements and accompanying notes, adjusted to give effect to the Distributions as if they had been consummated on January 1, 2018. The pro forma adjustments impacting pro forma Operating EBITDA reflect the impact of various supply agreements ("supply agreements") entered into in connection with the Dow Distribution and are outlined in the preceding section, Supplemental Unaudited Pro Forma Combined Financial Information, as adjustments to "Cost of sales." The impact of these supply agreements is reflected in pro forma Operating EBITDA for the periods noted above as it is included in the measure of profit/loss reviewed by the CODM in order to show meaningful comparability among periods while assessing performance and making resource allocation decisions. There were no pro forma adjustments for the three and six months ended June 30, 2020 and for the three months ended June 30, 2019.
ELECTRONICS & IMAGING
The Electronics & Imaging segment is a leading global supplier of differentiated materials and systems for a broad range of consumer electronics including mobile devices, television monitors, personal computers and electronics used in a variety of industries. The segment is a leading provider of materials and solutions for the fabrication of semiconductors and integrated circuits, and provides innovative metallization processes for metal finishing, decorative, and industrial applications. Electronics & Imaging is a leading provider of platemaking systems and photopolymer plates for the packaging graphics industry and digital printing inks for a variety of applications in the textile, commercial printing, and home-office markets. In addition, the segment provides cutting-edge materials for the manufacturing of rigid and flexible displays for organic light emitting diode ("OLED"), and other display applications.
In millions
| Electronics & Imaging | Three Months Ended June 30, 2020 | June 30, 2019 | Six Months Ended June 30, 2020 | June 30, 2019 |
|---|---|---|---|---|
| Net sales | $905 | $858 | $1,789 | $1,683 |
| Operating EBITDA 1 | $277 | $246 | $530 | $534 |
| Equity earnings | $10 | $5 | $19 | $8 |
1. For the six months ended June 30, 2019, operating EBITDA is on a pro forma basis.
| Electronics & Imaging Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2020 |
|---|---|---|
| Local price & product mix | —% | —% |
| Currency | (1) | (1) |
| Volume | 7 | 7 |
| Portfolio & other | (1) | — |
| Total | 5% | 6% |
Electronics & Imaging net sales were $905 million for the three months ended June 30, 2020, up 5 percent from $858 million for the three months ended June 30, 2019. Net sales increased due to a 7 percent increase in volume partially offset by a 1 percent portfolio decline and a 1 percent unfavorable currency impact. Volume growth was driven by Semiconductor Technologies with continued strength in the logic and foundry segment and increased memory demand in servers and data centers. Within Image Solutions, volume gains in ink for the consumer market were mostly offset by declined demand for flexographic printing and OLED materials. Volume declined within Interconnect Solutions due to softness in smartphones and select industrial markets.
Operating EBITDA was $277 million for the three months ended June 30, 2020, up 13 percent compared with $246 million for the three months ended June 30, 2019 due to volume gains and cost productivity actions.
Electronics & Imaging net sales were $1,789 million for the six months ended June 30, 2020, up 6 percent from $1,683 million for the six months ended June 30, 2019. Net sales increased due to a 7 percent volume growth offset by a 1 percent unfavorable currency impact, driven primarily by Asia Pacific. Volume growth in Semiconductor Technologies was driven by the logic and foundry segment and increased demand for memory in servers and data centers was partially offset by volume declines in Image Solutions.
Operating EBITDA was $530 million for the six months ended June 30, 2020, down 1 percent compared with pro forma Operating EBITDA of $534 million for the six months ended June 30, 2019. Favorable impacts from volume gains and cost productivity actions were offset by higher raw material costs and the absence of $51 million in income related to an asset sale in 2019.
NUTRITION & BIOSCIENCES
The Nutrition & Biosciences segment is an innovation-driven and customer-focused segment that provides solutions for the global food and beverage, dietary supplements, home and personal care, energy, animal nutrition and pharma markets. The segment is one of the world's largest producers of specialty ingredients, developing and manufacturing solutions for the global food and beverage, dietary supplements, enzymes and pharmaceutical excipient markets. Additionally, the segment is an industry pioneer and innovator that works with customers to improve the performance, productivity and sustainability of their products and processes, through differentiated technology in ingredients applications, fermentation, biotechnology, chemistry and manufacturing process excellence.
In millions
| Nutrition & Biosciences | Three Months Ended June 30, 2020 | June 30, 2019 | Six Months Ended June 30, 2020 | June 30, 2019 |
|---|---|---|---|---|
| Net sales | $1,539 | $1,558 | $3,090 | $3,093 |
| Operating EBITDA 1 | $418 | $386 | $803 | $735 |
| Equity earnings | $1 | $— | $1 | $— |
1. For the six months ended June 30, 2019, operating EBITDA is on a pro forma basis.
| Nutrition & Biosciences Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2020 |
|---|---|---|
| Local price & product mix | —% | 1% |
| Currency | (2) | (2) |
| Volume | 1 | 1 |
| Portfolio & other | — | — |
| Total | (1)% | —% |
Nutrition & Biosciences net sales were $1,539 million for the three months ended June 30, 2020, down 1 percent from $1,558 million for the three months ended June 30, 2019 due to a 1 percent increase in volume more than offset by a 2 percent unfavorable currency impact. Volume gains in Food & Beverage were driven by increased demand in the plant-based meat category partially offset by declines in sweeteners. Pharma Solutions volume increased due to demand in over-the-counter and prescription pharma applications. Health & Biosciences volume gains were driven by probiotics along with strong demand in home & personal care and animal nutrition offset by declined demand in biorefinery and microbial control.
Operating EBITDA was $418 million for the three months ended June 30, 2020, up 8 percent compared with $386 million for the three months ended June 30, 2019 due to a favorable product mix led by Health & Biosciences and cost productivity actions.
Nutrition & Biosciences net sales were $3,090 million for the six months ended June 30, 2020, or essentially flat compared with $3,093 million for the six months ended June 30, 2019. A 1 percent increase in local price and a 1 percent increase in volume were offset by a 2 percent unfavorable currency impact, driven primarily from EMEA. Health & Biosciences volume gains were driven by probiotics along with strong demand in home & personal care and animal nutrition, partially offset by declined demand in biorefinery and microbial control. Volume gains in Food & Beverage were driven by increased demand in the plant-based meat category partially offset by declines in sweeteners.
Operating EBITDA was $803 million for the six months ended June 30, 2020, up 9 percent compared with pro forma Operating EBITDA of $735 million for the six months ended June 30, 2019 due to a favorable product mix led by Health & Biosciences, pricing gains, and cost productivity actions.
TRANSPORTATION & INDUSTRIAL
The Transportation & Industrial segment provides high-performance engineering resins, adhesives, silicones, lubricants and parts to engineers and designers in the transportation, electronics, healthcare, industrial and consumer end-markets to enable systems solutions for demanding applications and environments. The segment delivers a broad range of polymer-based high-performance materials in its product portfolio, including elastomers and thermoplastic and thermoset engineering polymers which are used by customers to fabricate components for mechanical, chemical and electrical systems. In addition, the segment produces innovative engineering polymer solutions, high performance parts, specialty silicones and differentiated adhesive technologies to meet customer specifications in automotive, aerospace, electronics, industrial, healthcare and consumer markets. Transportation & Industrial is a global leader of advanced materials that provides technologies that differentiate customers’ products with improved performance characteristics enabling the transition to hybrid-electric-connected vehicles, high speed high frequency connectivity and smart healthcare.
In millions
| Transportation & Industrial | Three Months Ended June 30, 2020 | June 30, 2019 | Six Months Ended June 30, 2020 | June 30, 2019 |
|---|---|---|---|---|
| Net sales | $832 | $1,269 | $1,976 | $2,586 |
| Operating EBITDA 1 | $49 | $357 | $357 | $730 |
| Equity earnings | $1 | $2 | $2 | $2 |
1. For the six months ended June 30, 2019, operating EBITDA is on a pro forma basis.
| Transportation & Industrial Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2020 |
|---|---|---|
| Local price & product mix | (5)% | (5)% |
| Currency | (1) | (1) |
| Volume | (28) | (18) |
| Portfolio & other | — | — |
| Total | (34)% | (24)% |
Transportation & Industrial net sales were $832 million for the three months ended June 30, 2020, down from $1,269 million for the three months ended June 30, 2019. The change in net sales was due to a 28 percent decrease in volume, a 5 percent decrease in local price, and a 1 percent unfavorable currency impact. Volume declines were primarily due to impact of the COVID-19 pandemic on the automotive industry and the other key industrial end markets.
Operating EBITDA was $49 million for the three months ended June 30, 2020, down 86 percent compared with $357 million for the three months ended June 30, 2019 driven primarily by approximately $130 million in charges associated with temporarily idling several manufacturing plants to align supply with demand as well as the impact of volume declines due to the COVID-19 pandemic.
Transportation & Industrial net sales were $1,976 million for the six months ended June 30, 2020, down from $2,586 million for the six months ended June 30, 2019 due to a 18 percent decrease in volume, a 5 percent decrease in local price, and a 1 percent unfavorable currency impact. Volume declines were primarily due to impact of the COVID-19 pandemic on the automotive industry and the other key industrial markets.
Operating EBITDA was $357 million for the six months ended June 30, 2020, down 51 percent compared with pro forma Operating EBITDA of $730 million for the six months ended June 30, 2019 driven primarily by volume declines due to the COVID-19 pandemic, price declines, and charges associated with temporarily idling several manufacturing plants to align supply with demand, as referenced above.
SAFETY & CONSTRUCTION
The Safety & Construction segment is a leading provider of engineered products and integrated systems for a number of industries including worker safety, water purification and separation, aerospace, energy, medical packaging and building materials. The segment satisfies the growing global needs of businesses, governments, and consumers for solutions that make life safer, healthier, and better. By uniting market-driven science with the strength of highly regarded brands, the segment strives to bring new products and solutions to solve customers' needs faster, better and more cost effectively.
In millions
| Safety & Construction | Three Months Ended June 30, 2020 | June 30, 2019 | Six Months Ended June 30, 2020 | June 30, 2019 |
|---|---|---|---|---|
| Net sales | $1,244 | $1,341 | $2,520 | $2,624 |
| Operating EBITDA 1 | $349 | $382 | $717 | $756 |
| Equity earnings | $5 | $7 | $12 | $15 |
1. For the six months ended June 30, 2019, operating EBITDA is on a pro forma basis.
| Safety & Construction Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2020 |
|---|---|---|
| Local price & product mix | 2% | 2% |
| Currency | (1) | (1) |
| Volume | (10) | (7) |
| Portfolio & other | 2 | 2 |
| Total | (7)% | (4)% |
Safety & Construction net sales were $1,244 million for the three months ended June 30, 2020, down from $1,341 million for the three months ended June 30, 2019 as a 2 percent increase in local price and a 2 percent increase in portfolio were more than offset by a 10 percent decline in volume and a 1 percent unfavorable impact from currency globally. The portfolio impact reflects the recent acquisitions in the Water Solutions business. Local price increased led by the Safety Solutions. Volume gains in Water Solutions and demand for TYVEK® protective garments were more than offset by volume declines in Safety and Shelter Solutions due to weakened demand across end markets and declined construction activity as a result of the COVID-19 pandemic.
Operating EBITDA was $349 million for the three months ended June 30, 2020, down 9 percent compared with $382 million for the three months ended June 30, 2019 due to lower volumes and costs associated with capacity reductions more than offsetting a favorable product mix and productivity actions.
Safety & Construction net sales were $2,520 million for the six months ended June 30, 2020, slightly down from $2,624 million for the six months ended June 30, 2019 as a 2 percent increase in local price and 2 percent increase in portfolio were more than offset by a 7 percent volume decline and a 1 percent unfavorable impact from currency. The portfolio impact reflects the recent acquisitions in the Water Solutions business. Volume growth in the segment was led by gains in Water Solutions and protective garment sales within Safety Solutions which were more than offset by weakened demand in end markets as a result of the COVID-19 pandemic. Shelter Solutions volume declined due to the COVID-19 pandemic and the resulting impact on construction activity.
Operating EBITDA was $717 million for the six months ended June 30, 2020, down 5 percent compared with pro forma Operating EBITDA of $756 million for the six months ended June 30, 2019 due to lower volumes, the absence of licensing income, and costs associated with capacity reductions more than offsetting pricing gains, improved product mix, and productivity actions.
NON-CORE
The Non-Core segment is a leading global supplier of key materials for the manufacturing of photovoltaic cells and panels, including innovative metallization pastes, backsheet materials and silicone encapsulants and adhesives. The segment also includes the Company's share of the results of the HSC Group, a U.S.-based group of companies that manufacture and sell polycrystalline silicon products for the photovoltaic and semiconductor industries. Additionally, the segment provides materials used in components and films for consumer electronics, automotive, and aerospace markets. The segment also provides sustainable materials and services for sulfuric acid production and regeneration technologies, alkylation technology for production of clean, high-octane gasoline, and a comprehensive suite of aftermarket service and solutions offerings, including safety consulting and services, to improve the safety, productivity, and sustainability of organizations across a range of industries. The Non-Core segment is also a leading producer of specialty biotechnology materials for carpet and apparel markets as well as polyester films for the healthcare, photovoltaics, electronics, packaging and labels, and electrical insulation industries.
In millions
| Non-Core | Three Months Ended June 30, 2020 | June 30, 2019 | Six Months Ended June 30, 2020 | June 30, 2019 |
|---|---|---|---|---|
| Net sales | $308 | $442 | $674 | $896 |
| Operating EBITDA 1 | $93 | $104 | $135 | $202 |
| Equity earnings 2 | $86 | $36 | $108 | $66 |
1. For the six months ended June 30, 2019, operating EBITDA is on a pro forma basis.
2. Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes a restructuring charge of $1 million and $2 million for the three and six months ended June 30, 2019 which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statements of Operations.
| Non-Core Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2020 |
|---|---|---|
| Local price & product mix | 2% | 2% |
| Currency | (1) | (1) |
| Volume | (22) | (17) |
| Portfolio & other | (9) | (9) |
| Total | (30)% | (25)% |
Non-Core net sales were $308 million for the three months ended June 30, 2020, down from $442 million for the three months ended June 30, 2019 due to 2 percent pricing gains more than offset by a 22 percent volume decline, a 9 percent portfolio decline, and a 1 percent unfavorable currency impact. The third quarter 2019 sale of the Sustainable Solutions business reduced sales by 9 percent. Volume gains in microcircuit paste materials were more than offset by declines in demand in trichlorosilane, TEDLAR® aircraft films and photovoltaic metallization pastes.
Operating EBITDA was $93 million for the three months ended June 30, 2020, down 11 percent compared with $104 million for the three months ended June 30, 2019 as a customer settlement gain of $64 million was more than offset by volume declines and the absence of earnings from the Sustainable Solutions business.
Non-Core net sales were $674 million for the six months ended June 30, 2020, down from $896 million for the six months ended June 30, 2019. Net sales declined due to a 17 percent decline in volume, a 9 percent portfolio decline due to the sale of the Sustainable Solutions business and a 1 percent unfavorable impact from currency, which more than offset a 2 percent increase in local price. Volume declines were driven by declines in demand for trichlorosilane and TEDLAR® aircraft films.
Operating EBITDA was $135 million for the six months ended June 30, 2020, down 33 percent compared with pro forma Operating EBITDA of $202 million for the six months ended June 30, 2019 as a customer settlement gain of $64 million was more than offset by volume declines and the absence of earnings from the Sustainable Solutions business.
CHANGES IN FINANCIAL CONDITION
Liquidity & Capital Resources
Information related to the Company's liquidity and capital resources can be found in the Company's 2019 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Liquidity and Capital Resources. Discussion below provides the updates to this information for the six months ended June 30, 2020.
The Company continually reviews its sources of liquidity and debt portfolio and may make adjustments to one or both to ensure adequate liquidity and increase the Company’s optionality and financing efficiency as it relates to financing cost and balancing terms/maturities. The Company’s primary source of incremental liquidity is cash flows from operating activities. COVID-19 continues to adversely impact the broader global economy, including negatively impacting economic growth and creating disruption and volatility in the global financial and capital markets, which could result in increases in the cost of capital and/or adversely impact the availability of and access to capital, which could negatively affect DuPont’s liquidity. Management expects the generation of cash from operations and the ability to access the debt capital markets and other sources of liquidity will continue to provide sufficient liquidity and financial flexibility to meet the Company’s and its subsidiaries obligations as they come due; however, DuPont is unable to predict the extent of COVID-19 related impacts which depends on highly uncertain and unpredictable future developments, including the duration and spread of the COVID-19 outbreak, and the speed and extent of the resumption of normal economic and operating conditions. In light of this uncertainty, the Company has taken steps to further ensure liquidity and capital resources, as discussed below.
In millions
| June 30, 2020 | December 31, 2019 | |
|---|---|---|
| Cash and cash equivalents | $3,737 | $1,540 |
| Total debt | $19,167 | $17,447 |
The Company's cash and cash equivalents at June 30, 2020 and December 31, 2019 were $3.7 billion and $1.5 billion, respectively, of which $1.4 billion at June 30, 2020 and December 31, 2019 were held by subsidiaries in foreign countries, including United States territories. For each of its foreign subsidiaries, the Company makes an assertion regarding the amount of earnings intended for permanent reinvestment, with the balance available to be repatriated to the United States. The increase in cash and cash equivalents was primarily due to receipt of proceeds from the May Debt Offering, discussed further below.
Total debt at June 30, 2020 and December 31, 2019 was $19.2 billion and $17.4 billion, respectively. The increase was primarily due to the May Debt Offering.
Term Loan and Revolving Credit Facilities
In November 2018, the Company entered into a term loan agreement that establishes two term loan facilities in the aggregate principal amount of $3 billion, (the “Term Loan Facilities”) as well as a five-year $3 billion revolving credit facility (the “Five-Year Revolving Credit Facility”). Effective May 2, 2019, the Company fully drew the two Term Loan Facilities in the aggregate principal amount of $3.0 billion and the Five-Year Revolving Credit Facility became effective and available. The Five-Year Revolving Credit Facility is generally expected to remain undrawn, and serve as a backstop to the Company’s commercial paper and letter of credit issuance. In June 2019, the Company entered into a 364-day $750 million revolving credit facility (the “Old 364-Day Revolving Credit Facility”).
In April 2020, the Company entered into a $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility"). The $1B Revolving Credit Facility replaced the Old 364-Day Revolving Credit Facility, improving the Company’s liquidity position in response to near term uncertainties. As of the effectiveness of the $1B Revolving Credit Facility, the Old 364-Day Revolving Credit Facility was terminated. The $1B Revolving Credit facility may be used for general corporate purposes.
Debt Offering
On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May Debt Offering”). The proceeds from the May Debt Offering are expected to be used by the Company to repay or redeem the Company’s $0.5 billion in floating rate notes due November 2020 and $1.5 billion of 3.77 percent fixed-rate notes due November 2020 (collectively, the “2020 Notes”). Upon consummation of the Intended N&B Transaction, the Company will be required to mail a notice of redemption to holders of the Notes, with a copy to the Trustee, setting forth the date of redemption of all of the Notes on the date (“Special Mandatory Redemption Date”) that is the later of (i) three (3) Business Days after the consummation of the Intended N&B Transaction and (ii) May 1, 2021. On the Special Mandatory Redemption Date, the Company will be required to redeem all of the Notes at a redemption price equal to 100% of the aggregate principal amount of the Notes plus accrued and unpaid interest, if any, up to but excluding the Special Mandatory Redemption Date. In the event a special mandatory redemption is triggered, the Company expects to fund the redemption with proceeds from the Special Cash Payment.
Commercial Paper
In April 2019, DuPont authorized a $3 billion commercial paper program (the “DuPont Commercial Paper Program”). At June 30, 2020, the Company had issued $1.6 billion of commercial paper ($1.8 billion at December 31, 2019).
Nutrition & Biosciences Financing
In connection with the Intended N&B Transaction, N&B Inc. entered into a Bridge Commitment Letter in an aggregate principal amount of $7.5 billion, (the “Bridge Loans”) to secure committed financing for the Special Cash Payment and related financing fees and expenses. The aggregate commitment under the Bridge Letter is reduced by, among other things, (1) the amount of net cash proceeds received by N&B Inc. from any issuance of senior unsecured notes pursuant to a Rule 144A offering or other private placement, (the "N&B Notes Offering") and (2) certain qualifying term loan commitments under senior unsecured term loan facilities.
In January 2020, N&B Inc. entered into a senior unsecured term loan agreement in the amount of $1.25 billion split evenly between three- and five-year facilities. As a result of entry into the term loan agreement, the commitments under the Bridge Commitment Letter were reduced to $6.25 billion. The remaining $6.25 billion is expected to be funded through the N&B Notes Offering and/or the Bridge Loans. The proceeds from drawdowns on the term loan facilities and the N&B Notes Offering, if any, and/or the Bridge Loans would be used to make the Special Cash Payment and to pay the related financing fees and expenses. The commitments under the Bridge Commitment Letter and the availability of funding under the term loan agreement are subject to customary closing conditions including among others, the satisfaction of substantially all the conditions to the consummation of the intended transaction with IFF.
Borrowing under the term loan agreement and, if any, under the Bridge Loans would occur immediately prior to the closing of the Intended N&B Transaction. Any issuance of the N&B Note Offering for some or all the remaining $6.25 billion would likely occur in the second half of 2020.
Pursuant to the Merger Agreement, the fees and expenses associated with the financing, including fees associated with any prepayment will be borne (A) entirely by N&B Inc. if the transaction closes; and (B) equally by DuPont and IFF if the Merger Agreement terminates. However, if the Merger Agreement is terminated by IFF, in accordance with its terms, for breach by DuPont, such fees and expenses will be borne entirely by DuPont; and if terminated by DuPont in accordance with its terms for breach by IFF, such fees and expenses will be borne entirely by IFF.
Credit Ratings
The Company's credit ratings impact its access to the debt capital markets and cost of capital. The Company remains committed to a strong financial position and strong investment-grade rating. At July 29, 2020, DuPont's credit ratings were as follows:
| Credit Ratings | Long-Term Rating | Short-Term Rating | Outlook |
| Standard & Poor’s | BBB+ | A-2 | Negative Watch |
| Moody’s Investors Service | Baa1 | P-2 | Stable |
| Fitch Ratings | BBB+ | F-2 | Stable |
The Company's indenture covenants related to its 2018 Senior Notes and May Debt Offering contains certain limitations on the Company’s ability to incur liens and enter into sale lease-back transactions, mergers and consolidations as well as customary events of default. The Term Loan Facilities, the Five-Year Revolving Credit Facility and the $1B Revolving Credit Facility contain a financial covenant, typical for companies with similar credit ratings, requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At June 30, 2020, the Company was in compliance with this financial covenant.
Summary of Cash Flows
The Company’s cash flows from operating, investing and financing activities, as reflected in the interim Consolidated Statements of Cash Flows, are summarized in the following table. The cash flows related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows for the six months ended June 30, 2019.
In millions
| Cash Flow Summary Cash provided by (used for): | Six Months Ended June 30, 2020 | 2019 |
|---|---|---|
| Operating activities | $1,520 | $(51) |
| Investing activities | $(348) | $(1,657) |
| Financing activities | $1,050 | $(10,661) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $(30) | $48 |
Cash Flows from Operating Activities
In the first six months of 2020, cash provided by operating activities was $1,520 million, compared with cash used for operating activities of $51 million in the same period last year. The increase in cash provided by operating activities was primarily due to a decrease in cash used for working capital, offset by the impact of the Dow and Corteva Distributions to period earnings.
| Net Working Capital In millions (except ratio) | June 30, 2020 | Dec 31, 2019 |
|---|---|---|
| Current assets | $11,986 | $9,999 |
| Current liabilities | 8,010 | 8,346 |
| Net working capital | $3,976 | $1,653 |
| Current ratio | 1.50:1 | 1.20:1 |
Cash Flows from Investing Activities
In the first six months of 2020, cash used for investing activities was $348 million, compared with $1,657 million in the first six months of 2019. The decrease in cash used was primarily attributable to lower capital expenditures and an increase in proceeds from sales of property and businesses. The first six months of 2019 also contains activity related to the materials science and agriculture businesses prior to the Distributions.
Cash Flows from Financing Activities
In the first six months of 2020, cash provided by financing activities was $1,050 million compared with cash used for financing activities of $10,661 million in the same period last year. The primary driver of the decrease in cash used was a reduction in cash payments related to the Distributions of Dow and Corteva, a reduction in payments on long-term debt, and a reduction in share repurchase of common stock, partially offset by decreased issuances of short-term notes payable and lower proceeds from issuance of long-term debt. The first six months of 2019 also contains activity related to the materials science and agriculture businesses prior to the Distributions.
Dividends
On February 12, 2020, the Board of Directors declared a first quarter dividend of $0.30 per share, paid on March 16, 2020, to shareholders of record on February 28, 2020.
On April 29, 2020, the Company announced that its Board declared a second quarter dividend of $0.30 per share, paid on June 15, 2020, to shareholders of record on May 29, 2020.
On June 25, 2020, the Company announced that its Board declared a third quarter dividend of $0.30 per share payable on September 15, 2020, to shareholders of record on July 31, 2020.
Share Buyback Programs
On June 1, 2019, the Company's Board of Directors authorized a new $2 billion share buyback program, which expires on June 1, 2021. During the second quarter, the Company did not repurchase any shares. As of June 30, 2020, the Company repurchased 16.9 million shares under this program since inception at a total cost of $982 million. See Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds, for additional information.
Pension and Other Post Employment Plans
DuPont expects to make additional contributions in the aggregate of approximately $45 million by year-end 2020 to certain non-US pension and other post employment benefit plans. Any such contribution could be funded by existing cash balances and/or cash from other available sources of liquidity.
Restructuring
In March 2020, the Company approved restructuring actions designed to capture near-term cost reductions following the expected closure of the Intended N&B Transaction (the "2020 Restructuring Program"). As a result of these actions, the Company recorded pre-tax restructuring charges of $126 million inception-to-date, consisting of severance and related benefit costs of $102 million and asset related charges of $24 million. The Company expects actions related to this program to be substantially complete by the end of 2020. Future cash payments related to the 2020 Restructuring Program are anticipated to be $81 million primarily related to the payment of severance and related benefits.
In June 2019, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the Distributions (the "2019 Restructuring Program"). As a result of these actions, the Company has recorded pre-tax restructuring charges of $140 million inception-to-date, consisting of severance and related benefit costs of $106 million and asset related charges of $34 million. Actions associated with the 2019 Restructuring Program are considered substantially complete. Future cash payments related to the 2019 Restructuring Program are anticipated to be $42 million, primarily related to the payment of severance and related benefits.
In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program, adopted by the DowDuPont Board of Directors. The DowDuPont Cost Synergy Program was designed to integrate and optimize the organization following the Merger and in preparation for the Distributions whereby the Company has recorded pre-tax restructuring charges attributable to the continuing operations of DuPont of $489 million inception-to-date, consisting of severance and related benefit costs of $213 million, asset related charges of $209 million and contract termination charges of $67 million. The activities related to the DowDuPont Cost Synergy Program are expected to result in additional cash expenditures of $41 million consisting of severance and related benefit costs and contract terminations. Actions associated with the DowDuPont Cost Synergy Program, including employee separations, are considered substantially complete (see Note 5 to the interim Consolidated Financial Statements).
Off-balance Sheet Arrangements
Guarantees arise in the ordinary course of business from relationships with customers and nonconsolidated affiliates when the Company undertakes an obligation to guarantee the performance of others if specific triggering events occur. At June 30, 2020 and December 31, 2019, the Company had directly guaranteed $176 million and $187 million, respectively, of such obligations. Additional information related to the guarantees of the Subsidiaries can be found in the “Guarantees” section of Note 13 to the interim Consolidated Financial Statements.
Contractual Obligations
Information related to the Company's contractual obligations at December 31, 2019 can be found in the Company's 2019 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Contractual Obligations. The Company completed the May Debt Offering during the second quarter of 2020. Refer to Liquidity & Capital Resources for more information. There were no other material changes to the Company's contractual obligations during the second quarter of 2020.
OTHER MATTERS
Recent Accounting Guidance
See Note 2 to the interim Consolidated Financial Statements for a description of recent accounting guidance.
Critical Accounting Estimates
The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make judgments, assumptions and estimates that affect the amounts reported in the interim Consolidated Financial Statements and accompanying notes. Note 1 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (“2019 Annual Report”) describes the significant accounting policies and methods used in the preparation of the Consolidated Financial Statements. DuPont’s accounting policies that are impacted by judgments, assumptions and estimates are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s 2019 Annual Report. Since December 31, 2019, there have been no material changes in the Company’s accounting policies that are impacted by judgments, assumptions and estimates. See the discussion in this section for information regarding the valuation of assets and impairment considerations.
Valuation of Assets and Impairment Considerations
The Company tests goodwill and indefinite-lived intangible assets for impairment annually during the fourth quarter as of October 1, or more frequently when events or changes in circumstances indicate that the fair value is below its carrying value. Goodwill is evaluated for impairment using qualitative and/or quantitative testing procedures. The Company performs goodwill impairment testing at the reporting unit level which is defined as the operating segment or one level below the operating segment. One level below the operating segment, or component, is a business in which discrete financial information is available and regularly reviewed by segment management. The Company aggregates certain components into reporting units based on economic similarities.
As a result of the related acquisition method of accounting in connection with the Merger, Historical EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment.
COVID-19 continues to adversely impact the broader global economy and has caused significant volatility in financial markets. If there is a of lack of recovery, the time period to recovery is longer than expected or further global softening is experienced in certain markets, such as automotive, aerospace, commercial construction, oil & gas and select industrial end-markets, or a sustained decline in the value of the Company's common stock, the Company may be required to perform additional impairment assessments for its goodwill, other intangibles, and long-lived assets, the results of which could result in material impairment charges.
Market risk
As filed, 324 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
See Note 19 to the interim Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the Company's 2019 Annual Report on Form 10-K for information on the Company's utilization of financial instruments and an analysis of the sensitivity of these instruments.
Controls and procedures
As filed, 1,969 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
The Company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the Company's reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
As of June 30, 2020, the Company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company's internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that was conducted during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
In connection with the Distributions, there were several processes, policies, operations, technologies and information systems that were integrated following the Merger which have been replicated, transferred or separated. During the quarter ended June 30, 2020, the Company continued to take steps to ensure that adequate controls were designed and maintained, including planning for separation activities related to the Intended N&B Transaction.
DuPont de Nemours Inc. PART II - OTHER INFORMATION
Risk factors
As filed, 3,737 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Other than the risk factor set forth below, there have been no material changes in the Company's risk factors discussed in Part I, Item 1A, Risk Factors, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
The extent to which the novel coronavirus (COVID-19) and measures taken in response to it, impact DuPont’s business, results of operations, access to sources of liquidity and financial condition depends on future developments, which are highly uncertain and cannot be predicted.
DuPont is actively monitoring the global impacts of COVID-19, including the impacts from responsive measures, and remains focused on its top priorities - the safety and health of its employees and the needs of its customers. The company’s business and financial condition, and the business and financial condition of the company’s customers and suppliers, have been impacted by the significantly increased economic and demand uncertainties created by the COVID-19 outbreak. In addition, public and private sector responsive measures, such as the imposition of travel restrictions, quarantines, adoption of remote working, and suspension of non-essential business and government services, have impacted the company’s business and financial condition. Many of DuPont’s facilities and employees are based in areas impacted by the virus. While most DuPont manufacturing sites remain in operation, DuPont has reduced or furloughed certain operations in response to government measures, employee welfare concerns and the impact of COVID-19 on the global demand and supply chain. DuPont’s manufacturing operations may be further adversely affected by impacts from COVID-19 including, among other things, additional government actions and other responsive measures, more and /or deeper supply chain disruptions, quarantines and health and availability of essential onsite personnel. Furthermore, COVID-19 continues to adversely impact the broader global economy, including negatively impacting economic growth and creating disruption and volatility in the global financial and capital markets, which could result in increases in the cost of capital and/or adversely impact the availability of and access to capital, which could negatively affect DuPont’s liquidity. DuPont is unable to predict the extent of COVID-19 related impacts on its business, results of operations, access to sources of liquidity and financial condition which depends on highly uncertain and unpredictable future developments, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume. DuPont’s financial results may be materially and adversely impacted by a variety of factors that have not yet been determined, including potential impairments of goodwill and other assets. DuPont is taking actions, including reducing costs, restructuring actions, and delaying certain capital expenditures and non-essential spend. In addition, the company may consider further reductions in or furloughing additional operations in response to further and/or deeper declines in demand and/or or supply chain disruptions. There can be no guaranty that such actions will significantly mitigate the impact of COVID-19 on the company’s business, results of operations, access to sources of liquidity or financial condition. After the COVID-19 outbreak has subsided, DuPont may experience materially adverse impacts to its business, results of operations and financial condition as a result of related global economic impacts, including any recession that has occurred or may occur in the future.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2020-04-01 to 2020-06-30 | $3.29bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2020-01-01 to 2020-06-30 | $6.61bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $209.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $445.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-04-01 to 2020-06-30 | $541.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2020-01-01 to 2020-06-30 | $1.17bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Income tax | 3 months2020-04-01 to 2020-06-30 | −$36.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2020-01-01 to 2020-06-30 | $8.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-04-01 to 2020-06-30 | −$2.48bn | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | −$3.09bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | −$3.37 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | −$4.20 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-04-01 to 2020-06-30 | −$3.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2020-01-01 to 2020-06-30 | −$4.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-04-01 to 2020-06-30 | 734,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2020-01-01 to 2020-06-30 | 736,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Cash and equivalents | At period end2020-06-30 | $3.74bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $11.99bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $66.75bn | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $8.01bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $29.18bn | us-gaap:Liabilities |
| Long-term debt | At period end2020-06-30 | −$17.61bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2020-06-30 | $3.56bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2020-06-30 | $37.01bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001666700-20-000042. Last ingested by Listed: Nov 10, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.